Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2482-2488

  Beddhu, Srinivasan ^a,b   Nigwekar, Sagar U ^c   Ma, Xilulian ^b   Greene, Tom ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Heart rate; Insulin resistance; Metabolic syndrome; Mortality

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART RATE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; NUTRITIONAL STATUS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STROKE;

CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67651121815     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp057     Document Type: Article

References (28)

1. Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
2. Ramkumar N, Cheung AK, Pappas LM et al. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr 2004; 14: 201-207
3. Beddhu S, Kimmel PL, Ramkumar N et al. Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005; 46: 577-586
4. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809
5. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22: C10-C13
6. Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536
7. Anderson EA, Hoffman RP, Balon TW et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-2252
8. Esler M, Straznicky N, Eikelis N et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48: 787-796
9. Eikelis N, Schlaich M, Aggarwal A et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079
10. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381
11. Muscelli E, Camastra S, Gastaldelli A et al. Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. Int J Obes Relat Metab Disord 1998; 22: 262-267
12. Kuo LE, Kitlinska JB, Tilan JU et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803-811
13. Benetos A, Rudnichi A, Thomas F et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999; 33: 44-52
14. Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-749
15. Gillman MW, Kannel WB, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154
16. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-830
17. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702
18. Levey AS, Bosch JP, Lewis JB et al. Modification of Diet in Renal Disease Study Group. Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470
19. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55
20. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497
21. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
22. National Heart, Lung and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual. ARIC Coordinating Center, School of Public Health, University of North Carolina, Chapel Hill, NC, 1987
23. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Section 5.4 Regression Splines. New York: Springer, 2000, 102-106
24. Goldberg RJ, Larson M, Levy D. The Framingham Study. Factors associated with survival to 75 years of age in middle-aged men and women. Arch Intern Med 1996; 156: 505-509
25. Kannel WB, Kannel C, Paffenbarger RS Jr et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-1494
26. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11: S19-S27
27. Chonchol M, Goldenberg I, Moss AJ et al. Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 2007; 27: 7-14
28. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359